Related Experiment Video
Updated: Jul 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Hamid Mithoowani1, Michela Febbraro2
1Grand River Regional Cancer Centre, 835 King St. W., Kitchener, ON N2G1G3, Canada.
Abstract:
Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.
Insights
This review covers recent advances in lung cancer screening, treatment, and immunotherapy for non-small cell lung cancer (NSCLC) in Canada. It highlights best practices for early, advanced, and metastatic disease management, including immunotherapy side effects.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Lung cancer is a leading cause of cancer death in Canada.
- Significant morbidity impacts patients and their families.
- Recent advancements have improved prevention, screening, and treatment.
Purpose of the Study:
- To provide a contemporary review of non-small cell lung cancer (NSCLC) treatment in Canada.
- To highlight recent data on lung cancer screening.
- To focus on the incorporation of immunotherapy and its toxicities.
Main Methods:
- Review of current best practices for NSCLC treatment in Canada.
- Analysis of recent data on screening, early-stage, locally-advanced, and metastatic disease management.
- Special emphasis on immunotherapy integration and toxicity management.
Main Results:
- Comprehensive overview of contemporary NSCLC treatment strategies.
- Inclusion of the latest findings in lung cancer screening protocols.
- Detailed examination of immunotherapy's role and associated adverse events.
Conclusions:
- Current best practices for NSCLC treatment in Canada are presented.
- Immunotherapy has become a key component in NSCLC management.
- Understanding and managing immunotherapy toxicities is crucial for patient care.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...